Table 2

Demographics, clinical, pathological and CSF data in FTLD-Tau and FTLD-TDP subgroups

FTLD-TauFTLD-TDP
Pick’s diseaseCBDPSPOther tauopathyP valuesABCNon-specifiedP values
n3795NA11185NA
Age at CSF collection (years)58.3 (5.8)57.6 (8.2)73.8 (7.3)72.6 (12.4)0.0173 (NA)65.1 (8.7)70.3 (9.8)62 (4.2)0.32
Sex (% female)33.342.922.20.00.39100.054.650.050.00.82
Education (years)16.7 (2.3)15.5 (3.1)16.1 (2.9)14 (5.4)0.8814 (NA)14.4 (2.3)16.5 (3.2)16.5 (2.1)0.43
Age at death (years)63.3 (6.8)60.1 (9)76.7 (8.6)82.4 (11.5)<0.0175 (NA)68 (10.3)74.4 (9.9)63 (2.8)0.32
% with no AD pathology (NIA-AA stage ≤B1)10010078600.2510056100800.11
Time interval, onset–CSF (years)4.3 (3.1)2.5 (1)4.3 (3.5)4.2 (2.7)0.481 (NA)4.5 (3.3)3.6 (1.8)2 (1.4)0.36
Time interval, CSF–death (years)5 (1.7)2.6 (1.5)2.9 (2.1)9.8 (3.3)0.012 (NA)2.9 (2.9)4.1 (2.2)1 (1.4)0.26
Total disease duration, onset–death (years)9.3 (4.7)5.3 (1.4)7.2 (4.7)14 (1)0.023 (NA)7.4 (3.1)7.8 (3)3 (0)0.19
sAPPβ (ng/mL)518.3 (141.9)452.2 (120.6)487.4 (112.9)470.7 (150.8)0.86415 (NA)533.9 (179.9)525.8 (121)441.2 (24.6)0.76
YKL-40 (ng/mL)269.3 (3.6)314.6 (57.7)314.4 (90.2)271 (59.6)0.24280.3 (NA)280.3 (48.6)251.2 (48.7)228.8 (54.9)0.54
sAPPβ:YKL-40 ratio1.92 (0.51)1.54 (0.71)1.63 (0.55)1.77 (0.49)0.471.48 (NA)1.9 (0.51)2.21 (0.8)2 (0.59)0.69
  • Unless otherwise specified, the results are expressed as mean (SD). Differences between subtypes were assessed by Kruskal-Wallis rank-sum test for numeric quantitative variables and χ2 test for categorical variables.

  • AD, Alzheimer’s disease;CBD, corticobasal degeneration; CSF, cerebrospinal fluid; FTLD, frontotemporal lobar degeneration;NA, not applicable;NIA-AA, National Institute on Aging and Alzheimer's Association; PSP, progressive supranuclear palsy; Tauopathy, argyrophilic grain disease (n=4) and unclassifiable tauopathy (n=1);sAPPβ, soluble β fragment of amyloid precursor protein.